StimCardio Raises $30M Series A for Wearable AFib Therapy Rhyvive

Los Angeles-based StimCardio Medical has closed an oversubscribed $30 million Series A to advance Rhyvive, an investigational wrist-worn therapy for atrial fibrillation (AF). The round was led by Metis Medtech, John Slump's family office.

Catalyst Health Ventures, several corporate strategic investors and other new and existing investors also participated. The company did not disclose a valuation or its total funding to date. Slump, CEO and founder of Metis Medtech, and Joshua Phillips, managing partner of Catalyst Health Ventures, both sit on StimCardio's board. Alongside its Los Angeles headquarters, the company runs a technology center in Austin and has an office in Israel.

CEO Amir Soltanianzadeh leads the company alongside founder and chief science officer Amos Ziv and co-founder and CTO Tsahi Holand. Alexei Mlodinow chairs the board, and electrophysiologist Prof. Vivek Y. Reddy serves as senior medical advisor. Phillips said the technology could reduce AF recurrence after catheter ablation, a significant unmet clinical need.

A Wrist-Worn Add-On to Ablation

Rhyvive is a closed-loop system that pairs physiological sensing with personalized, non-invasive stimulation of the median nerve, targeting autonomic pathways involved in AF. It is designed as an adjunct to catheter ablation, extending treatment beyond the procedure room and into patients' homes.

The problem it targets is recurrence. The company cites 30% to 40% of patients experiencing a return of the arrhythmia after ablation, and a 2025 JACC analysis estimating that about 59 million people worldwide live with AF.

"Our vision is to establish non-invasive neuromodulation as a new therapeutic category in cardiac electrophysiology," said Soltanianzadeh.

From NeuroPulse 1 to a Pivotal Trial

StimCardio's case rests on NeuroPulse 1, a randomized, double-blind, sham-controlled pilot study presented as a late-breaking trial at HRX Live 2026 and published in Heart Rhythm. Active stimulation produced a statistically significant reduction in recurrent atrial arrhythmia events compared with sham.

The new capital is meant to carry the company through NeuroPulse 2, a multicenter pivotal trial that will test whether adding wearable neuromodulation to ablation improves outcomes versus ablation alone, and through preparation of a De Novo submission to the FDA. Rhyvive remains an investigational device, limited by U.S. law to investigational use. Medical Device Network reported that the company also plans to extend the technology to other AF and cardiovascular indications.

Why It Matters

The lead investor brings a relevant track record. Metis Medtech's Slump has four major medical device exits totaling more than $1.25 billion in aggregate M&A value, including two in cardiac electrophysiology, Farapulse and Atraverse Medical, the market StimCardio is entering.

"StimCardio is pioneering innovative technology positioned to disrupt the cardiac electrophysiology arena," Slump said.

By the company's figures, 30% to 40% of ablation patients still see the arrhythmia return. StimCardio is betting that a non-invasive, at-home wearable can improve results after the procedure rather than compete with it. The pivotal trial will determine whether that pilot signal holds at scale and whether Rhyvive can open a new device category in electrophysiology.

Source

PR Newswire — StimCardio Closes Oversubscribed $30 Million Series A Financing to Advance Wearable Therapeutic for Atrial Fibrillation